metabolix inc (MBLX:NASDAQ GM)

Executive Profile*

Background*

Dr. Anthony J. Sinskey Sc.D. is a Co-founder of Metabolix Inc., Telpho, Merrimack Pharmaceuticals Inc., and Tepha Inc. Dr. Sinskey serves as Advisor of LS9, Inc. He served as a Scientific Co-Founder of Genzyme Corporation. Dr. Sinskey serves as a Consultant to several fine chemicals and pharmaceuticals companies. He is a Professor of Microbiology in the Department of Biology and Professor of Health Sciences and Technology at the Harvard-M.I.T. Division Health Sciences ... and Technology Program. Since 1968, Dr. Sinskey has been on the faculty of the Massachusetts Institute of Technology. Dr.Sinskey serves as a Co-Director of the Malaysia-MIT Biotechnology Partnership Program and as Co-Director of the Center for Biomedical Innovation. He is a Co-Director of M.I.T.'s Program on the Pharmaceutical Industry (POPI). Dr. Sinskey serves as Professor of Health Sciences and Technology at the Harvard-MIT Division of HST. He has helped to found many successful biotechnology companies including Genzyme and Aspen Technology. Dr. Sinskey serves as an Editor and Co-founder of Metabolic Engineering, as Editor of Process Biochemistry, and a Member of the Editorial boards of Pharmaceutical Discovery and Applied Microbiology and Biotechnology. He serves as the Chairman of Natural Pharmaceuticals, Inc. He has been a Director of Apex Bioventures Acquisition Corp., since June 1, 2006. Dr. Sinskey has been a Director at Metabolix Inc. since June 1992. He has been Director of Merrimack Pharmaceuticals, Inc. since 1999. Dr. Sinskey serves as Director of Tepha Inc. and Cambridge Devices Inc. He is an Advisor to Serono's Strategic Education Direction, VIMAC Ventures, and the Business Development Bank of Canada. Dr. Sinskey serves as a Member of Scientific Advisory Board of Akermin, Inc. He serves as a Member of Advisory Board of MIT Center for Biomedical Innovation and Kodiak Venture Partners. He serves as a Member of Scientific Advisory Board at Knome, Inc. He serves as Advisor of Brain Resource Limited. He serves as Member of Scientific Advisory Board at QRxPharma Pty Ltd. He has been a Member of Advisory Board at SweetWater Energy, Inc. since March 9, 2012. He served as Member of Scientific Advisory Board at LS9, Inc. He served as a Member of Scientific Advisory Board of Transition Therapeutics Inc. His post-doctoral work was done at the Harvard School of Public Health. Dr. Sinskey received a Sc.D. from Massachusetts Institute of Technology in 1966 and a B.S. from the University of Illinois.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
MBLX:US	$1.73 USD	-0.02

COMPETITOR COMPENSATION